Trial Profile

A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms CA048-001
Sponsors Bristol-Myers Squibb

Most Recent Events

19 Oct 2022 Status changed from active, no longer recruiting to completed.
02 Dec 2021 Planned End Date changed from 15 Aug 2025 to 31 Aug 2022.
02 Dec 2021 Planned primary completion date changed from 30 Jun 2024 to 30 Aug 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com